日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild-type Acute Myeloid Leukemias

Quizartinib 和 Milademetan 联合抑制 FLT3-ITD 和 MDM2 对 FLT3-ITD 突变/TP53 野生型急性髓系白血病具有协同作用

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-24-2764
Zhang, Weiguo; Li, Li; Muftuoglu, Muharrem; Basyal, Mahesh; Togashi, Noriko; Iwanaga, Koichi; Tanzawa, Fumie; Numata, Masashi; Bixby, Dale L; Erba, Harry P; Podoltsev, Nikolai; Schiller, Gary J; Kumar, Prasanna; Lesegretain, Arnaud; Isoyama, Takeshi; Seki, Takahiko; Daver, Naval; Andreeff, Michael
白血病
MDM2
P53
FLT3
发表日期：2025
文献求助 收藏

Cost-effectiveness of upfront vs delayed allogeneic hematopoietic stem cell transplant for intermediate risk AML

对于中危急性髓系白血病患者，早期异基因造血干细胞移植与延迟异基因造血干细胞移植的成本效益分析

期刊:Blood Advances
影响因子:7.1
doi:10.1182/bloodadvances.2025016532
Alhajahjeh, Abdulrahman; Patel, Kishan K; Podoltsev, Nikolai A; Kewan, Tariq; Stempel, Jessica M; Mendez, Lourdes; Seropian, Stuart; Gowda, Lohith; Huntington, Scott F; Stahl, Maximilian; Zeidan, Amer M; Goshua, George; Bewersdorf, Jan Philipp
白血病
细胞生物学
发育与干细胞
干细胞
发表日期：2025
文献求助 收藏

Luspatercept for patients with lower-risk myelodysplastic syndromes/neoplasms: a systematic review and meta-analysis

Luspatercept 用于低危骨髓增生异常综合征/肿瘤患者：系统评价和荟萃分析

期刊:Blood Advances
影响因子:7.1
doi:10.1182/bloodadvances.2025017611
Alhajahjeh, Abdulrahman; Woite, Naira Link; Rolles, Benjamin; Stempel, Jessica M; Mina, Alain; Mendez, Lourdes; Kewan, Tariq; Podoltsev, Nikolai A; Stahl, Maximilian; Grimshaw, Alyssa A; Zeidan, Amer M; Bewersdorf, Jan Philipp
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Integrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine ± Durvalumab

对接受阿扎胞苷±度伐利尤单抗治疗的RNA剪接因子突变型急性髓系白血病和高危骨髓增生异常综合征进行整合免疫图谱分析

期刊:Therapeutic Advances in Hematology
影响因子:3.1
doi:10.1177/20406207251347344
Bewersdorf, Jan Philipp; Hasle, Vanessa; Shallis, Rory M; Thompson, Ethan; Lopes de Menezes, Daniel; Rose, Shelonitda; Boss, Isaac; Mendez, Lourdes; Podoltsev, Nikolai; Stahl, Maximilian; Kewan, Tariq; Halene, Stephanie; Haferlach, Torsten; Fox, Brian A; Zeidan, Amer M
白血病
免疫/内分泌
发表日期：2025
文献求助 收藏

Calcineurin inhibitor and eltrombopag combination for acquired aplastic anemia: results from a large national database

钙调磷酸酶抑制剂联合艾曲波帕治疗获得性再生障碍性贫血：来自大型国家数据库的结果

期刊:Therapeutic Advances in Hematology
影响因子:3.1
doi:10.1177/20406207251394775
Stempel, Jessica M; Wang, Rong; Lee, Alfred I; Zeidan, Amer M; Ma, Xiaomei; Podoltsev, Nikolai A
贫血
代谢
发表日期：2025
文献求助 收藏

A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial

一项在美国和加拿大开展的多中心研究旨在评估罗培干扰素α-2b-njft治疗原发性血小板增多症患者的疗效、安全性和耐受性：EXCEED-ET试验

期刊:Frontiers in Medicine
影响因子:3
doi:10.3389/fmed.2025.1548590
Masarova, Lucia; Reeves, Brandi N; El Chaer, Firas; Foltz, Lynda; Tashi, Tsewang; Abu-Zeinah, Ghaith; Lucas, Jennifer; Halpern, Anna B; Maze, Dawn; Qin, Albert; Safah, Hana; Lan, Fengshuo; O'Connell, Casey L; Goel, Swati; Rein, Lindsay; Fang, Bruno; How, Joan; Babu, Sunil; Li, Zhuoyan; Cerquozzi, Sonia; Oh, Stephen T; Hunter, Anthony M; Podoltsev, Nikolai; Vachhani, Pankit; Yacoub, Abdulraheem; Cunningham, Julia M; Hillis, Christopher; Otoukesh, Salman; Zagrijtschuk, Oleh; Castro, Henry; Bose, Prithviraj
血小板
EED
发表日期：2025
文献求助 收藏

Selinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study design

Selinexor联合ruxolitinib治疗JAK抑制剂初治骨髓纤维化：SENTRY 3期研究设计

期刊:Future Oncology
影响因子:2.6
doi:10.1080/14796694.2025.2461393
Mascarenhas, John; Maher, Keri; Rampal, Raajit; Bose, Prithviraj; Podoltsev, Nikolai; Hong, Junshik; Chai, Yi; Kye, Steve; Method, Michael; Harrison, Claire
JAK/STAT
发表日期：2025
文献求助 收藏

Initial management of patients with acquired aplastic anemia in the United States: results from a large national claims database

美国获得性再生障碍性贫血患者的初始管理：来自大型全国索赔数据库的结果

期刊:Annals of Hematology
影响因子:2.4
doi:10.1007/s00277-025-06307-z
Stempel, Jessica M; Wang, Rong; Lee, Alfred I; Zeidan, Amer M; Ma, Xiaomei; Podoltsev, Nikolai A
贫血
代谢
发表日期：2025
文献求助 收藏

Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AML

Enasidenib 与常规治疗相比，在老年 IDH2 突变型难治性/复发性 AML 患者中的成本效益分析

期刊:Leukemia & Lymphoma
影响因子:2.2
doi:10.1080/10428194.2024.2426073
Alhajahjeh, Abdulrahman; Patel, Kishan K; Shallis, Rory M; Podoltsev, Nikolai A; Kewan, Tariq; Stempel, Jessica M; Mendez, Lourdes; Huntington, Scott F; Stahl, Maximilian; Goshua, George; Bewersdorf, Jan Philipp; Zeidan, Amer M
发表日期：2025
文献求助 收藏

Second malignancies among older patients with classical myeloproliferative neoplasms treated with ruxolitinib

接受鲁索替尼治疗的老年经典骨髓增生性肿瘤患者的继发性恶性肿瘤

期刊:
影响因子:
doi:10.1016/j.bneo.2025.100159
Wang, Rong; Stempel, Jessica M; Shallis, Rory M; Huntington, Scott F; Zeidan, Amer M; Neparidze, Natalia; Di, Mengyang; Bewersdorf, Jan Philipp; Mendez, Lourdes; Ma, Xiaomei; Podoltsev, Nikolai A
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏